全文获取类型
收费全文 | 1269699篇 |
免费 | 99754篇 |
国内免费 | 1980篇 |
专业分类
耳鼻咽喉 | 18405篇 |
儿科学 | 44239篇 |
妇产科学 | 34992篇 |
基础医学 | 180911篇 |
口腔科学 | 33557篇 |
临床医学 | 110610篇 |
内科学 | 256104篇 |
皮肤病学 | 28004篇 |
神经病学 | 99706篇 |
特种医学 | 51164篇 |
外国民族医学 | 660篇 |
外科学 | 195719篇 |
综合类 | 27022篇 |
现状与发展 | 1篇 |
一般理论 | 377篇 |
预防医学 | 95137篇 |
眼科学 | 27795篇 |
药学 | 94520篇 |
2篇 | |
中国医学 | 2336篇 |
肿瘤学 | 70172篇 |
出版年
2018年 | 13123篇 |
2017年 | 9961篇 |
2016年 | 10895篇 |
2015年 | 12369篇 |
2014年 | 17162篇 |
2013年 | 26208篇 |
2012年 | 36016篇 |
2011年 | 38050篇 |
2010年 | 22798篇 |
2009年 | 21806篇 |
2008年 | 36633篇 |
2007年 | 39243篇 |
2006年 | 39498篇 |
2005年 | 38437篇 |
2004年 | 37589篇 |
2003年 | 36343篇 |
2002年 | 35702篇 |
2001年 | 63888篇 |
2000年 | 66318篇 |
1999年 | 56060篇 |
1998年 | 14354篇 |
1997年 | 12987篇 |
1996年 | 13405篇 |
1995年 | 13383篇 |
1994年 | 12718篇 |
1993年 | 11725篇 |
1992年 | 44500篇 |
1991年 | 43453篇 |
1990年 | 42202篇 |
1989年 | 40089篇 |
1988年 | 36864篇 |
1987年 | 36218篇 |
1986年 | 33591篇 |
1985年 | 32263篇 |
1984年 | 24118篇 |
1983年 | 20215篇 |
1982年 | 11682篇 |
1981年 | 10638篇 |
1980年 | 9459篇 |
1979年 | 21299篇 |
1978年 | 14785篇 |
1977年 | 12489篇 |
1976年 | 11667篇 |
1975年 | 12600篇 |
1974年 | 14643篇 |
1973年 | 14101篇 |
1972年 | 12938篇 |
1971年 | 11714篇 |
1970年 | 11039篇 |
1969年 | 10012篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
23.
24.
25.
26.
Rajiv V. Dave Baek Kim Alona Courtney Rachel OConnell Tim Rattay Vicky P. Taxiarchi Jamie J. Kirkham Elizabeth M. Camacho Patricia Fairbrother Nisha Sharma Christopher W. J. Cartlidge Kieran Horgan Stuart A. McIntosh Daniel R. Leff Raghavan Vidya Shelley Potter Chris Holcombe Ellen Copson Charlotte E. Coles Ramsey I. Cutress Ashu Gandhi Cliona C. Kirwan 《British journal of cancer》2021,124(11):1785
Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting.Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey.Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.Subject terms: Breast cancer, Surgical oncology, Health care economics, Quality of life, Health policy 相似文献
27.
J. Barnett I. Pulzato M. Javed Y.J. Lee A. Choraria S.V. Kemp A. Rice S. Jordan P.L. Shah A.G. Nicholson S. Padley A. Devaraj 《Clinical radiology》2021,76(1):77.e9-77.e15
28.
29.
José-Luis Andréu María Auxiliadora Martín Héctor Corominas José Javier Pérez-Venegas José Andrés Román-Ivorra Fernando Sánchez-Alonso Ángel Gil de Miguel 《Reumatología clinica》2021,17(4):212-214
IntroductionThe current paradigm of the management of rheumatoid arthritis (RA) recommends achieving a state of remission or low disease activity through the treat-to-target strategy. Our study assesses adherence to this strategy.MethodPatients with RA (ACR-EULAR 2010 criteria) were included. From each centre, 19 patients were randomly selected. Clinical histories (CH) were assessed by independent auditors, checking compliance with predefined quality criteria. The study was approved by ethics committees.ResultsWe included 856 patients (mean age 54 years; 71% women). The use of a combined index (CI) was recorded in 61% of cases. Visits were recorded every 4 weeks using a CI in 4% of CH while attempts were made to achieve remission. Monitoring of disease activity every 6–8 months after reaching the target was recorded in 73% of cases.ConclusionsThe implementation of the treat-to-target strategy is barely recorded in patients with RA in routine clinical practice. 相似文献
30.
Balázs Nemes Réka P. Szabó Dávid Péntek Ildikó Nagy Gergely Ivády Bettina Kárai Eszter Szánthó Zsuzsa Hevessy Sándor Sipka Gergő J. Szőllősi Sándor Baráth 《Transplantation proceedings》2021,53(5):1423-1432
IntroductionThe usage of extended-criteria donors (ECD) became a routinely accepted manner in the last decade. ECD is a potential risk factor for antibody-mediated rejection. Analysis of lymphocyte subsets might be a complementary diagnostic toolkit because there is limited knowledge about this term.MethodBetween May 12, 2016, and September 4, 2019, a total of 130 patients who had undergone kidney transplant were investigated. Patients were divided in ECD and standard criteria donor (SCD) groups. Blood samples were collected before the operation, then in the first week and after 30, 60, 180, and 365 days. Besides routine laboratory tests, multicolor flow cytometry was performed for lymphocyte subsets.ResultsECD grafts were transplanted to older recipients. The number of CD4+ cells increased in the SCDs from the first week to until the end of first month, and then decreased. The number of CD4+ cells decreased from the beginning of the study until the end of first year to 66% of its original value in ECDs. At the first month, the number of CD19+ cells was higher in SCD compared with ECD cases; the number then decreased in both groups. T-regulatory cells had a drop at the first week that lasted until the first month. A bigger increase in SCD and a moderate increase in ECD group were then observed. The kinetics of CD19+ and CD19+ naive cells are similar in the ECD and SCD groups. In the SCD group, cell count decreased in both CD19+ (13%) and CD19+ naive (12%) between third and sixth month. The count of CD19+ cells decreased by 9%, but the count of CD19+ naive cells increased by 11% between the sixth month and first year.DiscussionThe prolonged postoperative uremic state caused by the poorer initial function, together with an aging immune system, explains the weaker immune response in ECD patients, which may be the cause of the decreased number of memory and regulatory T cells. Older patients with an ECD graft need a tailored, personalized, and less aggressive immunosuppressive treatment. 相似文献